Apigenin, a flavonoid compound found in chamomile tea, has become a cornerstone ingredient in sleep supplements and anti-aging protocols promoted by wellness influencers and health practitioners. However, a comprehensive analysis of available research reveals a significant disconnect between marketing claims and peer-reviewed clinical evidence.
A PubMed analysis spanning 2000-2024 identified 127 animal studies and 89 cell culture studies examining apigenin, yet only 23 human trials investigating any endpoint have been published. More notably, just 4 human clinical trials have specifically examined apigenin’s effects on sleep quality. While the compound does bind to benzodiazepine receptors in the brain—similar to pharmaceutical sleep medications—its lower binding affinity raises questions about clinical efficacy in real-world settings.
Researchers emphasize that while chamomile extract showed modest sleep improvements in elderly populations, isolating apigenin’s specific contribution remains unclear due to inconsistent methodologies across small-scale studies.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Apigenin Sleep and Longevity Claims Face Scientific Scrutiny →
